The Company
Khondrion primary focuses on the development of therapies for inherited mitochondrial diseases, including Leigh Disease, MELAS, Leber’s Hereditary Optic Neuropathy and Friedreich Ataxia.
Our company's focus is on our own product development programmes. We have extensive experience in mitochondrial medicine, unique quantitative live-cell imaging technologies and in-depth, characterised human cell panels. Moreover, we have also developed a portfolio of pre-clinical drug candidates that are in the process of entering clinical phase. As a second activity we provide mitochondrial/compound related services to third parties like the development of new cell biological read-outs and compound research and testing.
Founded in 2012 and located in Nijmegen, The Netherlands, our company benefits from an exclusive collaboration with the Nijmegen Centre for Mitochondrial Disorders (NCMD) at the Radboud University Nijmegen Medical Centre and national and international Foundations. The NCMD is internationally known as a leading full-facility expert center for clinical care, biochemical, pathological and molecular diagnostics and research on patients with disturbances to their mitochondrial energy metabolism. These strategic and long-term alliances ensure a close interaction between research, diagnostic, patient facilities, and patient organisations and allows us to maintain a scientific link with other internationally recognised mitochondrial medicine expert centers across the globe.
Our company's focus is on our own product development programmes. We have extensive experience in mitochondrial medicine, unique quantitative live-cell imaging technologies and in-depth, characterised human cell panels. Moreover, we have also developed a portfolio of pre-clinical drug candidates that are in the process of entering clinical phase. As a second activity we provide mitochondrial/compound related services to third parties like the development of new cell biological read-outs and compound research and testing.
Founded in 2012 and located in Nijmegen, The Netherlands, our company benefits from an exclusive collaboration with the Nijmegen Centre for Mitochondrial Disorders (NCMD) at the Radboud University Nijmegen Medical Centre and national and international Foundations. The NCMD is internationally known as a leading full-facility expert center for clinical care, biochemical, pathological and molecular diagnostics and research on patients with disturbances to their mitochondrial energy metabolism. These strategic and long-term alliances ensure a close interaction between research, diagnostic, patient facilities, and patient organisations and allows us to maintain a scientific link with other internationally recognised mitochondrial medicine expert centers across the globe.
